These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15743193)

  • 1. NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide.
    Deshmukh MV; Voll G; Kühlewein A; Mäcke H; Schmitt J; Kessler H; Gemmecker G
    J Med Chem; 2005 Mar; 48(5):1506-14. PubMed ID: 15743193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational analyses of sandostatin analogs containing stereochemical changes in positions 6 or 8.
    Mattern RH; Zhang L; Rueter JK; Goodman M
    Biopolymers; 2000 May; 53(6):506-22. PubMed ID: 10775066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
    Capello A; Krenning EP; Breeman WA; Bernard BF; Konijnenberg MW; de Jong M
    Cancer Biother Radiopharm; 2003 Oct; 18(5):761-8. PubMed ID: 14629824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
    J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.
    Paganelli G; Bodei L; Handkiewicz Junak D; Rocca P; Papi S; Lopera Sierra M; Gatti M; Chinol M; Bartolomei M; Fiorenza M; Grana C
    Biopolymers; 2002; 66(6):393-8. PubMed ID: 12658726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule.
    Perico ME; Chinol M; Nacca A; Luison E; Paganelli G; Canevari S
    J Nucl Med; 2001 Nov; 42(11):1697-703. PubMed ID: 11696642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, potentiometric, kinetic, and NMR Studies of 1,4,7,10-tetraazacyclododecane-1,7-bis(acetic acid)-4,10-bis(methylenephosphonic acid) (DO2A2P) and its complexes with Ca(II), Cu(II), Zn(II) and lanthanide(III) ions.
    Kálmán FK; Baranyai Z; Tóth I; Bányai I; Király R; Brücher E; Aime S; Sun X; Sherry AD; Kovács Z
    Inorg Chem; 2008 May; 47(9):3851-62. PubMed ID: 18380456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
    Reubi JC; Schär JC; Waser B; Wenger S; Heppeler A; Schmitt JS; Mäcke HR
    Eur J Nucl Med; 2000 Mar; 27(3):273-82. PubMed ID: 10774879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational analysis of a potent SSTR3-selective somatostatin analogue by NMR in water solution.
    Gairí M; Saiz P; Madurga S; Roig X; Erchegyi J; Koerber SC; Reubi JC; Rivier JE; Giralt E
    J Pept Sci; 2006 Feb; 12(2):82-91. PubMed ID: 16365912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic analogue approach to metallobleomycins: syntheses, structure and properties of mononuclear and tetranuclear gallium(III) complexes of a ligand that resembles the metal-binding site of bleomycin.
    Manessi A; Papaefstathiou GS; Raptopoulou CP; Terzis A; Zafiropoulos TF
    J Inorg Biochem; 2004 Dec; 98(12):2052-62. PubMed ID: 15541494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A refined model for the somatostatin pharmacophore: conformational analysis of lanthionine-sandostatin analogs.
    Melacini G; Zhu Q; Osapay G; Goodman M
    J Med Chem; 1997 Jul; 40(14):2252-8. PubMed ID: 9216844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount.
    de Jong M; Breeman WA; Bernard BF; van Gameren A; de Bruin E; Bakker WH; van der Pluijm ME; Visser TJ; Mäcke HR; Krenning EP
    Eur J Nucl Med; 1999 Jul; 26(7):693-8. PubMed ID: 10398816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiconformational NMR analysis of sandostatin (octreotide): equilibrium between beta-sheet and partially helical structures.
    Melacini G; Zhu Q; Goodman M
    Biochemistry; 1997 Feb; 36(6):1233-41. PubMed ID: 9063871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
    Heppeler A; André JP; Buschmann I; Wang X; Reubi JC; Hennig M; Kaden TA; Maecke HR
    Chemistry; 2008; 14(10):3026-34. PubMed ID: 18246556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo.
    Schottelius M; Reubi JC; Eltschinger V; Schwaiger M; Wester HJ
    J Med Chem; 2005 Apr; 48(8):2778-89. PubMed ID: 15828816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An 86Y-labeled mirror-image oligonucleotide: influence of Y-DOTA isomers on the biodistribution in rats.
    Schlesinger J; Koezle I; Bergmann R; Tamburini S; Bolzati C; Tisato F; Noll B; Klussmann S; Vonhoff S; Wuest F; Pietzsch HJ; Steinbach J
    Bioconjug Chem; 2008 Apr; 19(4):928-39. PubMed ID: 18345604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural study of Ga(III), In(III), and Fe(III) complexes of triaza-macrocycle based ligands with N3S3 donor set.
    Notni J; Pohle K; Peters JA; Görls H; Platas-Iglesias C
    Inorg Chem; 2009 Apr; 48(7):3257-67. PubMed ID: 19281197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.